Arsela Prelaj

2.6k total citations
82 papers, 1.0k citations indexed

About

Arsela Prelaj is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Arsela Prelaj has authored 82 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 52 papers in Oncology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Arsela Prelaj's work include Lung Cancer Treatments and Mutations (34 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Lung Cancer Research Studies (23 papers). Arsela Prelaj is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Lung Cancer Research Studies (23 papers). Arsela Prelaj collaborates with scholars based in Italy, United States and France. Arsela Prelaj's co-authors include Roberto Ferrara, Raffaele Califano, Rebecca Tay, Benjamin Besse, Marina Chiara Garassino, Nathalie Chaput, Diego Signorelli, Giuseppe Lo Russo, Claudia Proto and Giulia Galli and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Arsela Prelaj

76 papers receiving 1000 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arsela Prelaj Italy	18	677	521	169	152	130	82	1.0k
Ashok K. Vaid India	15	781 1.2×	455 0.9×	188 1.1×	259 1.7×	108 0.8×	54	1.1k
Jacob Sands United States	21	651 1.0×	511 1.0×	232 1.4×	161 1.1×	56 0.4×	80	1.0k
Elisa Zanardi Italy	16	355 0.5×	420 0.8×	177 1.0×	170 1.1×	79 0.6×	56	785
Filippo Gustavo Dall’Olio Italy	13	610 0.9×	433 0.8×	178 1.1×	229 1.5×	136 1.0×	39	956
Alex Guminski Australia	16	709 1.0×	445 0.9×	272 1.6×	201 1.3×	128 1.0×	35	1.1k
Alexandros Xyrafas Switzerland	16	766 1.1×	314 0.6×	185 1.1×	267 1.8×	209 1.6×	38	1.1k
Shikai Wu China	18	461 0.7×	284 0.5×	159 0.9×	186 1.2×	97 0.7×	73	796
Suchita Pakkala United States	15	685 1.0×	522 1.0×	154 0.9×	100 0.7×	120 0.9×	32	973
Koung Jin Suh South Korea	18	786 1.2×	475 0.9×	271 1.6×	215 1.4×	124 1.0×	98	1.2k
Angela Takano Singapore	16	376 0.6×	425 0.8×	230 1.4×	171 1.1×	76 0.6×	51	906

Countries citing papers authored by Arsela Prelaj

Since Specialization

Citations

This map shows the geographic impact of Arsela Prelaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arsela Prelaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arsela Prelaj more than expected).

Fields of papers citing papers by Arsela Prelaj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arsela Prelaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arsela Prelaj. The network helps show where Arsela Prelaj may publish in the future.

Co-authorship network of co-authors of Arsela Prelaj

This figure shows the co-authorship network connecting the top 25 collaborators of Arsela Prelaj. A scholar is included among the top collaborators of Arsela Prelaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arsela Prelaj. Arsela Prelaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Proto, Claudia, Giuseppe Lo Russo, Arsela Prelaj, et al.. (2025). Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 9(9). e2400790–e2400790. 1 indexed citations

Proto, Claudia, Arsela Prelaj, Laura Mazzeo, et al.. (2025). 40P: Metformin plus/minus cyclic fasting mimicking diet to improve the efficacy of first-line chemo-immunotherapy in advanced LKB1-inactive NSCLC: Results of the phase II trial FAME. Journal of Thoracic Oncology. 20(3). S36–S37. 1 indexed citations

Miceli, Rosalba, Hanna Eriksson, Giuseppe Lo Russo, et al.. (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. 63. 213–219. 3 indexed citations

Occhipinti, Mario, Marta Brambilla, Raimondo Di Liello, et al.. (2024). Unleashing precision: A review of targeted approaches in pleural mesothelioma. Critical Reviews in Oncology/Hematology. 203. 104481–104481. 6 indexed citations

Pellat, Anna, Thomas Grinda, Arsela Prelaj, et al.. (2024). Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours. SHILAP Revista de lepidopterología. 6. 100091–100091. 1 indexed citations

Lorenzini, Daniele, Mario Occhipinti, Sara Manglaviti, et al.. (2023). 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib. Annals of Oncology. 34. S779–S779. 1 indexed citations

Cornelissen, Robin, Arsela Prelaj, Sophie Sun, et al.. (2023). Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology. 18(8). 1031–1041. 34 indexed citations

Castelo-Branco, Luís, Gilberto Morgan, Arsela Prelaj, et al.. (2023). Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions. ESMO Open. 8(1). 100764–100764. 7 indexed citations

Pellat, Anna, Thomas Grinda, Arsela Prelaj, et al.. (2023). 1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group. Annals of Oncology. 34. S925–S925. 5 indexed citations

10.

Kumar, Kirthika Senthil, V. Miskovic, Agata Blasiak, et al.. (2023). Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment. American Society of Clinical Oncology Educational Book. 43(43). e390084–e390084. 33 indexed citations

11.

Rebuzzi, Sara Elena, Arsela Prelaj, Alex Friedlaender, et al.. (2022). Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Critical Reviews in Oncology/Hematology. 179. 103806–103806. 19 indexed citations

12.

Zattarin, Emma, Sara Manglaviti, Laura Mazzeo, et al.. (2022). Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncology. 18(23). 2593–2604. 3 indexed citations

13.

Toma, Alessandro De, Giuseppe Lo Russo, Diego Signorelli, et al.. (2021). Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology. 160. 103299–103299. 5 indexed citations

14.

Rebuzzi, Sara Elena, Lodovica Zullo, Giovanni Rossi, et al.. (2021). Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 22(5). 2625–2625. 40 indexed citations

15.

Provenzano, Leonardo, Valeria Cuccarini, Marco Platania, et al.. (2021). Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma. Tumori Journal. 107(6). NP136–NP140. 1 indexed citations

16.

Perrone, Fabiana, Lorenzo Belluomini, Marco Mazzotta, et al.. (2021). Exploring the role of respiratory microbiome in lung cancer: A systematic review. Critical Reviews in Oncology/Hematology. 164. 103404–103404. 24 indexed citations

17.

Ferrara, Roberto, Diego Signorelli, Claudia Proto, et al.. (2021). Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Translational Lung Cancer Research. 10(6). 2955–2969. 6 indexed citations

18.

Occhipinti, Mario, Marta Brambilla, Giulia Galli, et al.. (2021). Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine. 11(5). 424–424. 8 indexed citations

19.

Cornelissen, Robin, Sanyuan Sun, Marina Chiara Garassino, et al.. (2021). LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4). Annals of Oncology. 32. S1324–S1324. 6 indexed citations

20.

Liu, Yang, Sen Yang, Jiuzhou Zhao, et al.. (2021). Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis. Translational Lung Cancer Research. 10(2). 914–925. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact